AR037080A1 - Compuestos utiles en el tratamiento de enfermedades inflamatorias,composiciones que los contienen, su uso en terapia, metodos de tratamiento, procesos de preparacion e intermediarios - Google Patents
Compuestos utiles en el tratamiento de enfermedades inflamatorias,composiciones que los contienen, su uso en terapia, metodos de tratamiento, procesos de preparacion e intermediariosInfo
- Publication number
- AR037080A1 AR037080A1 ARP010104603A ARP010104603A AR037080A1 AR 037080 A1 AR037080 A1 AR 037080A1 AR P010104603 A ARP010104603 A AR P010104603A AR P010104603 A ARP010104603 A AR P010104603A AR 037080 A1 AR037080 A1 AR 037080A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- aryl
- heteroaryl
- group
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
Abstract
Compuestos de la fórmula (1), en la que: R1 representa alquilo C1-6, alquenilo C2-6, alquinilo C2-6, aril-Y1-, heteroaril-Y1-, aril-(O)t-aril-Y1, aril-(O)t-heteroaril-Y1-, heteroaril-(O)t-aril-Y1-, heteroaril-(O)t-heteroaril-Y1-, aril-SO2-Y1-, (alquil C1-6)-G-Y1-, heteroaril-G-aril-Y1-, J1-SO2-Y1-, R17O(CO)-(alquenil C2-6)-Y1-, R17NHCO-Y1-, R17NHSO2-Y1-, (alquinil C2-6)-Y1-, (alquenil C2-6)-Y1-, aril-O-Y1-, heteroaril-O-Y1-, (alquil C1-6)-SO2-Y1-, M-Y1-, J1-Y1-, J1-CO-Y1-, aril-CO-Y1- ó (cicloalquil C3-8)-Y1- ó (cicloalquenil C3-8)-Y1-; cuyos grupos alquinilo C2-6 y (alquinil C2-6)-Y1 pueden estar opcionalmente sustituidos con un grupo -OR17, cuyo grupo alquenilo C2-6 puede estar opcionalmente sustituido con uno o más grupos -COOR17, y cuyos grupos cicloalquilo o cicloalquenilo pueden estar opcionalmente sustituidos con uno o más grupos hidroxilo o alquilo C1-6; R2 representa hidrógeno o alquilo C1-6 opcionalmente sustituido con un grupo hidroxilo; R3 representa hidrógeno o alquilo C1-6; ó R1 y R2 pueden, conjuntamente con el átomo de nitrógeno al cual están unidos, formar un grupo de la fórmula J2, en donde el átomo de nitrógeno sustituya ya sea a X1 ó X2; t representa 0 ó 1; X representa etileno o un grupo de la fórmula CReRf donde Re y Rf independientemente representan hidrógeno o alquilo C1-4, ó Re y Rf pueden, conjuntamente con el átomo de carbono al cual están unidos, formar un grupo cicloalquilo C3-8; R4 y R5 representan independientemente hidrógeno o alquilo C1-4; Z representa un enlace, CO, SO2, CR10R7(CH2)n, (CH2)nCR10R7, CHR7(CH2)nO, CHR7(CH2)nS, CHR7(CH2)nOCO, CHR7(CH2)nCO, COCHR7(CH2)n ó S2CHR7(CH2)n; R6 representa alquilo C1-6, alquenilo C2-6, aril heteroarilo, aril-(alquenilo C2-6)-, -CN ó un grupo de la fórmula -Y2-J3; R7 representa hidrógeno, alquilo C1-4, CONR8R9 ó COO (alquilo C1-8); a y b representan 1 ó 2, tal que a + b representa 2 ó 3; G representa -SO2-, -SO2NR18, -NR18SO2-, -NR18CO-, CO ó -CONR18-; n representa un número entero de 0 a 4; M representa un grupo cicloalquilo C3-8 ó cicloalquenilo C3-8 fusionado a un grupo arilo monocíclico o heteroarilo monocíclico; J1, J2 y J3 independientemente representan una porción de la fórmula (2) en donde X1 representa oxígeno, NR11 ó azufre, X2 representa CH2, oxígeno, NR12 ó azufre, m1 representa un número entero de 1 a 3 y m2 representa un número entero de 1 a 3; con la condición de que m1 + m2 esté en el intervalo de 3 a 5, también con la condición de que cuando X1 y X2 representen oxígeno, NR11, NR12 o azufre, m1 y m2 deben ambos no ser menor de 2, en donde la fórmula 2 está opcionalmente sustituida con uno o más (por ejemplo 1 ó 2) grupos -Y3-arilo, -Y3-heteroarilo, -Y3-CO-arilo, -CO(cicloalquilo C3-8), -Y3-CO-heteroarilo, -alquilo C1-6, -Y3-COO (alquilo C1-6), -Y3-CO(alquilo C1-6), -Y3-W, -Y3-CO-W-, -Y3-NR15R16, -Y3-CONR15R16, hidroxilo, oxo, -Y3-SO2NR15R16, -Y3-SO2(alquilo C1-6), -Y3-SO2-arilo, -Y3-SO2heteroarilo, -Y3-NR13 (alquilo C1-6), -Y3-NR13SO2 (alquilo C1-6), -Y3-NR13CONR15R16, -Y3-NR13COOR14 ó -Y3-OCONR15R16, y está opcionalmente fusionado a un anillo arilo o heteroarilo monocíclicos; R8, R9, R10, R11, R12, R13 y R14 independientemente representan hidrógeno o alquilo C1-6; R15 y R16 representan independientemente hidrógeno o alquilo C1-6 o R15 y R16 conjuntamente con el átomo de nitrógeno al cual están unidos pueden formar un anillo de morfolina, piperidina o pirrolidina; R17 y R18 independientemente representan hidrógeno ó alquilo C1-6; W representa un anillo saturado o insaturado, no aromático de 5 a 7 miembros, que contiene entre 1 y 3 heteroátomos seleccionados de nitrógeno, oxígeno o azufre; opcionalmente sustituidos con uno o más grupos alquilo C1-6, halógeno o hidroxilo; Y1, Y2 e Y3 representan independientemente un enlace o un grupo de la fórmula -(CH2)pCRcRd(CH2)q- en donde Rc y Rd representan independientemente hidrógeno ó alquilo C1-4, ó Rc y Rd pueden, conjuntamente con el átomo de carbono al cual están unidos, formar un grupo cicloalquilo C3-8 y p y q representan independientemente un número entero de 0 a 5 en donde p + q es un número entero de 0 a 5; con la condición de que el compuesto de la fórmula (1) no sea un compuesto de la fórmula (3), en donde R2' representa hidrógeno o alquilo C1-4; R3' representa hidrógeno; X' representa metileno o etileno; a' y b' ambos representan 1; R4' y R5' ambos representan hidrógeno; y en donde la porción -Z'-R6' representa halobencilo; y las sales y solvatos de los mismos; los procesos para la preparación de los mismos, las composiciones que los contienen, su uso en terapia para el tratamiento de enfermedades inflamatorios, métodos de tratamiento, proceso de preparación e intermediarios.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0023973A GB0023973D0 (en) | 2000-09-29 | 2000-09-29 | Therapeutically useful compounds |
GB0107643A GB0107643D0 (en) | 2001-03-27 | 2001-03-27 | Therapeutically useful compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
AR037080A1 true AR037080A1 (es) | 2004-10-20 |
Family
ID=26245081
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP010104603A AR037080A1 (es) | 2000-09-29 | 2001-09-28 | Compuestos utiles en el tratamiento de enfermedades inflamatorias,composiciones que los contienen, su uso en terapia, metodos de tratamiento, procesos de preparacion e intermediarios |
Country Status (20)
Country | Link |
---|---|
US (1) | US7157457B2 (es) |
EP (2) | EP1586567A1 (es) |
JP (1) | JP5069392B2 (es) |
KR (1) | KR20030040510A (es) |
CN (1) | CN1478084A (es) |
AR (1) | AR037080A1 (es) |
AT (1) | ATE345331T1 (es) |
AU (1) | AU2001290146A1 (es) |
BR (1) | BR0114321A (es) |
CA (1) | CA2423305A1 (es) |
CZ (1) | CZ20031194A3 (es) |
DE (1) | DE60124576T2 (es) |
ES (1) | ES2275729T3 (es) |
HU (1) | HUP0303107A2 (es) |
IL (1) | IL155092A0 (es) |
MX (1) | MXPA03002813A (es) |
NO (1) | NO20031443L (es) |
NZ (1) | NZ525055A (es) |
PL (1) | PL362984A1 (es) |
WO (1) | WO2002026723A1 (es) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0207450D0 (en) * | 2002-03-28 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
US6858593B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
US6777399B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
US6787532B2 (en) | 2000-08-05 | 2004-09-07 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivatives |
US6759398B2 (en) | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
US6858596B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivative |
US6750210B2 (en) | 2000-08-05 | 2004-06-15 | Smithkline Beecham Corporation | Formulation containing novel anti-inflammatory androstane derivative |
US6777400B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
GB0207436D0 (en) * | 2002-03-28 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
TW200400035A (en) * | 2002-03-28 | 2004-01-01 | Glaxo Group Ltd | Novel compounds |
GB0207449D0 (en) * | 2002-03-28 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
GB0207432D0 (en) * | 2002-03-28 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
GB0207447D0 (en) * | 2002-03-28 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
GB0207439D0 (en) * | 2002-03-28 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
GB0211759D0 (en) * | 2002-05-22 | 2002-07-03 | Glaxo Group Ltd | Novel compounds |
GB0212357D0 (en) * | 2002-05-29 | 2002-07-10 | Glaxo Group Ltd | Novel compounds |
GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
WO2004028530A1 (en) | 2002-09-26 | 2004-04-08 | Bristol-Myers Squibb Company | N-substituted heterocyclic amines as modulators of chemokine receptor activity |
DE60329831D1 (de) * | 2003-06-10 | 2009-12-10 | Biondi Ricardo Miguel | Verwendung einer Verbingung gemäss Formel I zur Herstellung einer pharmazeutischen Zubereitung |
WO2005021515A2 (en) | 2003-08-29 | 2005-03-10 | Ranbaxy Laboratories Limited | Inhibitors of phosphodiesterase type-iv |
PT1801108E (pt) | 2004-09-08 | 2012-12-03 | Mitsubishi Tanabe Pharma Corp | Composto de morfolina para o tratamento de inflamações |
EP1992628A1 (en) | 2007-05-18 | 2008-11-19 | Glaxo Group Limited | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones |
EP1958947A1 (en) | 2007-02-15 | 2008-08-20 | Ranbaxy Laboratories Limited | Inhibitors of phosphodiesterase type 4 |
CA2680360A1 (en) * | 2007-03-13 | 2008-09-18 | Arete Therapeutics, Inc. | 4-piperidinylurea compounds as soluble epoxide hydrolase inhibitors |
US8273766B2 (en) | 2007-04-04 | 2012-09-25 | Kowa Company, Ltd. | Tetrahydroisoquinoline compound |
KR20100093104A (ko) | 2007-12-05 | 2010-08-24 | 아스트라제네카 아베 | 항비만제로서의 피페라진 |
CN102015668A (zh) | 2007-12-05 | 2011-04-13 | 阿斯利康(瑞典)有限公司 | 用作瘦蛋白受体调节剂的哌嗪衍生物及其用途 |
RU2014126070A (ru) | 2011-12-01 | 2016-01-27 | Глэксо Груп Лимитед | Способы лечения и предотвращения глазных заболеваний |
FR3022142B1 (fr) | 2014-06-16 | 2019-07-12 | Universite Paul Sabatier - Toulouse Iii | Inhibition de la chimiokine ccl7 ou de son recepteur ccr3 pour le traitement et le diagnostic du cancer de la prostate |
KR20170043603A (ko) | 2014-08-22 | 2017-04-21 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 네이세리아 고노레아에 감염을 치료하기 위한 트리시클릭 질소 함유 화합물 |
US20190336489A1 (en) | 2017-01-17 | 2019-11-07 | Glaxosmithkline Intellectual Property Development Limited | Non peptide heterobivalent molecules for treating inflammatory diseases |
TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法 |
CN111269340B (zh) * | 2020-03-31 | 2020-12-29 | 台州学院 | 一种以1-甲烷磺酰哌嗪为配体的螯合树脂及其制备方法和应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3087763B2 (ja) | 1990-11-30 | 2000-09-11 | 三井化学株式会社 | 新規な複素環式化合物およびそれを含有する医薬組成物 |
JPH04247074A (ja) * | 1991-02-01 | 1992-09-03 | Yoshitomi Pharmaceut Ind Ltd | 4−モルホリノ安息香酸誘導体の製造法 |
JPH04270272A (ja) * | 1991-02-25 | 1992-09-25 | Yoshitomi Pharmaceut Ind Ltd | アミノアルキルモルホリン誘導体の製造法 |
US5753654A (en) * | 1994-05-18 | 1998-05-19 | Nisshin Flour Milling Co., Ltd. | Diaminomethylidene derivatives |
KR970703301A (ko) | 1994-05-18 | 1997-07-03 | 쇼오다 오사무 | 신규 디아미노메틸리덴 유도체(novel diamincmethylidene derivative) |
DE59803108D1 (de) * | 1997-11-12 | 2002-03-21 | Bayer Ag | 2-phenyl-substituierte imidazotriazinone als phosphodiesterase inhibitoren |
EP1131288A1 (en) * | 1998-11-20 | 2001-09-12 | F. Hoffmann-La Roche Ag | Pyrrolidine derivatives-ccr-3 receptor antagonists |
WO2000035449A1 (en) * | 1998-12-18 | 2000-06-22 | Du Pont Pharmaceuticals Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
US6441001B1 (en) * | 1998-12-18 | 2002-08-27 | Bristol-Myers Squibb Pharma Company | 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity |
-
2001
- 2001-09-28 BR BR0114321-2A patent/BR0114321A/pt not_active IP Right Cessation
- 2001-09-28 CN CNA018196489A patent/CN1478084A/zh active Pending
- 2001-09-28 AR ARP010104603A patent/AR037080A1/es not_active Application Discontinuation
- 2001-09-28 AT AT01970027T patent/ATE345331T1/de not_active IP Right Cessation
- 2001-09-28 AU AU2001290146A patent/AU2001290146A1/en not_active Abandoned
- 2001-09-28 WO PCT/GB2001/004350 patent/WO2002026723A1/en not_active Application Discontinuation
- 2001-09-28 ES ES01970027T patent/ES2275729T3/es not_active Expired - Lifetime
- 2001-09-28 CZ CZ20031194A patent/CZ20031194A3/cs unknown
- 2001-09-28 IL IL15509201A patent/IL155092A0/xx unknown
- 2001-09-28 HU HU0303107A patent/HUP0303107A2/hu unknown
- 2001-09-28 EP EP05076503A patent/EP1586567A1/en not_active Withdrawn
- 2001-09-28 EP EP01970027A patent/EP1324991B1/en not_active Expired - Lifetime
- 2001-09-28 PL PL01362984A patent/PL362984A1/xx not_active Application Discontinuation
- 2001-09-28 NZ NZ525055A patent/NZ525055A/en unknown
- 2001-09-28 MX MXPA03002813A patent/MXPA03002813A/es unknown
- 2001-09-28 DE DE60124576T patent/DE60124576T2/de not_active Expired - Lifetime
- 2001-09-28 US US10/381,871 patent/US7157457B2/en not_active Expired - Lifetime
- 2001-09-28 CA CA002423305A patent/CA2423305A1/en not_active Abandoned
- 2001-09-28 KR KR10-2003-7004593A patent/KR20030040510A/ko not_active Application Discontinuation
- 2001-09-28 JP JP2002531107A patent/JP5069392B2/ja not_active Expired - Lifetime
-
2003
- 2003-03-28 NO NO20031443A patent/NO20031443L/no unknown
Also Published As
Publication number | Publication date |
---|---|
CZ20031194A3 (cs) | 2003-08-13 |
ES2275729T3 (es) | 2007-06-16 |
NO20031443L (no) | 2003-05-26 |
AU2001290146A1 (en) | 2002-04-08 |
NO20031443D0 (no) | 2003-03-28 |
JP2004509953A (ja) | 2004-04-02 |
EP1324991A1 (en) | 2003-07-09 |
PL362984A1 (en) | 2004-11-15 |
KR20030040510A (ko) | 2003-05-22 |
US20040058907A1 (en) | 2004-03-25 |
EP1586567A1 (en) | 2005-10-19 |
EP1324991B1 (en) | 2006-11-15 |
CA2423305A1 (en) | 2002-04-04 |
IL155092A0 (en) | 2003-10-31 |
ATE345331T1 (de) | 2006-12-15 |
DE60124576D1 (de) | 2006-12-28 |
BR0114321A (pt) | 2003-07-01 |
CN1478084A (zh) | 2004-02-25 |
DE60124576T2 (de) | 2007-06-21 |
JP5069392B2 (ja) | 2012-11-07 |
WO2002026723A1 (en) | 2002-04-04 |
NZ525055A (en) | 2004-09-24 |
MXPA03002813A (es) | 2003-10-15 |
HUP0303107A2 (hu) | 2004-03-01 |
US7157457B2 (en) | 2007-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR037080A1 (es) | Compuestos utiles en el tratamiento de enfermedades inflamatorias,composiciones que los contienen, su uso en terapia, metodos de tratamiento, procesos de preparacion e intermediarios | |
AR035205A1 (es) | Compuestos utiles en el tratamiento de enfermedades inflamatorias, proceso para su preparacion, intermediarios y composiciones farmaceuticas | |
AR034268A1 (es) | Compuestos derivados de piperidina, su uso en preparacion de medicamentos, composicion farmaceutica, metodo de tratamiento y proceso para su preparacion | |
AR065772A1 (es) | Compuestos de indolobenzazepina para el tratamiento de la hepatitis c. composiciones farmaceuticas. | |
AR035617A1 (es) | Compuestos derivados de fenetanolamina, combinaciones y formulaciones farmaceuticas de los mismos, proceso para su preparacion, su uso en la preparacion de medicamentos para el tratamiento o profilaxis de una condicion clinica para la cual se indica un agonista beta2 adreno-receptor e intermediarios | |
AR040047A1 (es) | 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de la 5-hidroxitriptamina-6 | |
HUP0203836A2 (hu) | 1,3-Diszubsztituált pirrolidin-származékok alfa2-adrenerg-receptor antagonista hatással, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
AR035933A1 (es) | Un compuesto derivado de fosfonato nucleosido aciclico, uso del mismo, un proceso para su preparacion y un compuesto de fosfonato. | |
AR010560A1 (es) | Compuestos derivados de nonoato donantes de oxido nitrico; composiciones farmaceuticas que los contienen; metodo para la dilatacion local de los vasossanguineos de mamiferos y metodo para matar o inactivar bacterias en la boca de un mamifero | |
AR017217A1 (es) | Compuestos antiarritmicos de bispidina, formulacion farmaceutica, uso de los mismos para preparar medicamentos, proceso para preparar dichos compuestos,compuestos intermediarios, y proceso para prepararlos | |
AR035235A1 (es) | Derivados heterocicliloxi-,-tioxi- y -aminobenzazol como ligandos de 5-hidroxitriptamina-6, un procedimiento para su preparacion, composicion farmaceutica, y el uso de dichos derivados para la manufactura de un medicamento | |
AR034283A1 (es) | Compuestos heterociclilindazol y azaindazol como ligandos de 5-hidroxitriptamina-6, un procedimiento para su preparacion, composicion farmaceutica y el uso de los mismos para la fabricacion de un medicamento | |
AR059571A1 (es) | Derivados de octahidro-pirrolo[3,4-c]pirrol, composiciones farmaceuticas | |
AR042169A1 (es) | Compuestos de pirazol utiles como inhibidores de proteinquinasa | |
CO5560559A2 (es) | Formulacion de suspension oral estabilizada | |
AR035313A1 (es) | Inhibidores de tace acetilenicos de acido hidroxamico de sulfonamida a base de alfa-aminoacidos, composiciones farmaceuticas y el uso de los mismos para la manufactura de medicamentos. | |
NO166129C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive tetrahydro-9h-pyrido (3,4-b)indoler. | |
AR019790A2 (es) | Compuestos derivados de la eritromicina, composiciones que los contienen. uso para preparar un medicamento | |
TR200000727T2 (tr) | 5HT geri alım inhibitörü ve h5-HT1B antagonistinin bir bileşimi. | |
DK1320526T3 (da) | Farmaceutisk aktive benzsulfonamidderivater som inhibitorer af protein-junkinaser | |
TR200000725T2 (tr) | Bir monoamin oksidaz inhibitörü ve h5-HT1B antagonistinin bileşimi | |
AR005279A1 (es) | Derivados 1-(piperidinil 1,2-disustituido)-4-(bencimidazolil e imidazopiridinil)-piperidina, proceso para su preparacion, composicion farmaceutica, y proceso para preparar dicha composicion | |
AR030239A1 (es) | Fta lidas substituidas, un procedimiento para su preparacion y composiciones farmaceuticas que contienen las mismas | |
NO983472L (no) | Taxoider, deres fremstilling og farmas°ytiske preparater inneholdende taxoidene | |
PT87300A (pt) | Benzo-und thieno-3,4-dihydro-pyridinderivate verfahren zu ihrer herstellung und diese verbindungen enthalte arzneimittel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |